The European Society for Medical Oncology (ESMO) has this month published new guidelines on the diagnosis, treatment and follow-up of people with chronic lymphocytic leukaemia (CLL).
The guidelines aim to make sure people with CLL receive the best available care. They have been written by a group of experts from hospitals across Europe and provide key recommendations on the management of CLL. They include guidance on the latest treatments for CLL based on up-to-date evidence from clinical trials.
Although the exact treatments that are available might vary from country to country, clinical guidelines help medical teams decide on the most appropriate treatment options for individual people based on reliable evidence.
For more information about how clinical evidence is collected, visit Lymphoma TrialsLink.
4 November 2020